Coiled Therapeutics Plc COIL
LSE · Birleşik Krallık · Sağlık Teknolojisi
GBp 7,40-0,10 (-%1,33)
Piyasa kapalı· · GBp · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Piyasa kapalı· · GBp · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
NEW YORK, NY / ACCESS Newswire / October 1, 2026 / today will host eight micro and small cap public companies and a select audience of institutional and other qualified investors in New York City for a full day of company presentations, one on one meetings, and networking.The investor focused conference provides meaningful access to executive management teams and differentiated small cap investment opportunities.
Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) said it expects to report the first safety data from a new version of its cancer drug AO-252 before the end of 2026. The developer of treatments for cancers driven by specific genetic changes plans to dose up to 30 patients with the new formulation...
Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) executive chairman Dr Sotirios Stergiopoulos spoke with Proactive's Stephen Gunnion about progress with the company's new drug formulation of AO-252, including the enrolment of the first six patients across the 120mg twice-daily and 160mg once-daily cohorts. Stergiopoulos explained that the initial cohorts are designed to provide important exposure data for the new formulation. The previous version had encountered solubility limitations as doses increased, restricting how much drug reached the patient, and Coiled is now looking to establish whether t
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.